School-based health centers (SBHCs) are an important setting to improve health through detecting, managing and preventing chronic illness. Too few people are vaccinated for the human papillomavirus (HPV), which can prevent tens of thousands of deaths from cancer each year. PEER will evaluate a program to increase health and wellness and the use of SBHCs for primary and preventive care. If successful, PEER could significantly increase the use of SBHCs, and decrease HPV-associated cancers and, thus, reduce the burden of cancer in the United States.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
4,000
Letter and fact sheet (infographic) mailed to caregivers of 9-14 year-olds and to teens 15-18, with optional phone call for "confidential patients" aged 15-18.
Clinic team/staff training based on qualitative interviews, recommended strategies and evidence-based interventions. Training materials include FAQs and Smart phrases. FAQs and informational sheets containing the same content as the mailers distributed in clinic to teen SBHC patients and their caregivers.
Educational sessions delivered in schools by OSBHA interns. Session content includes SBHC information and HPV awareness.
Kaiser Permanente Center for Health Research
Portland, Oregon, United States
Rate of Vaccination for HPV (n of patients with HPV vaccination/n of patients eligible for vaccination)
Vaccination among eligible clinic patients, and time to vaccination
Time frame: 6 and 12 months
Rates of new patients to the clinic (n of new patients/n of established patients)
New patients seen (vs. prior seen pts.) - New patient characteristics (age, rural)
Time frame: 6 and 12 months
Rate of use of other SBHC services (primary care visits, wellness assessments) (n of patients with primary care visits/n of new and established patients)
Use of other SBHC services and visits among eligible clinic patients
Time frame: 6 and 12 months
Rate of vaccination for other adolescent vaccinations (COVID-19, flu, Meningitis, or uptick of other vax's (TDAP, MMR, etc.)) (n of patients with additional vaccination among new and eligible clinic patients)
Vaccination among eligible clinic patients, and time to vaccination
Time frame: 6 and 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.